Future Market Insights predicts that the global Severe Asthma Treatment market demand will witness a CAGR of 5.1% from 2023 to 2033, reaching a value of US$ 36.18 billion by 2033. With the advent of biologics and targeted medications, Severe Asthma Treatment has seen a significant transformation, bringing hope to millions of people worldwide who suffer from the disease.
Biologics, derived from living organisms, have emerged as a promising advancement in Severe Asthma Treatment by targeting specific immune system pathways that cause inflammation in the airways. These drugs have demonstrated high efficacy in clinical trials and are increasingly being used to treat severe asthma patients who do not respond well to conventional therapies.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16760
Omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab are some of the most widely used biologics for Severe Asthma Treatment. Administered through subcutaneous injections or intravenous infusion, these drugs have been shown to improve lung function, reduce asthma exacerbations, and enhance overall quality of life for severe asthma patients.
As more people are diagnosed with severe asthma and new innovative treatments become available, the global Severe Asthma Treatment market is expected to continue to grow in the coming years.
Key Takeaways from the Market Study
- The Severe Asthma Treatment market is estimated to grow at a 5.1% CAGR from 2023 to 2033.
- In 2023, the inhaled route of administration is estimated to account for 40% of the severe asthma therapy market.
- In 2023, North America is estimated to hold 45% of the market for severe asthma therapy.
- In 2023, Europe’s Severe Asthma Treatment market is estimated to account for 39% of the total.
“Advancements in treatments along with innovation of treatment options is expected to favor the growth of the market in the upcoming years.” states an FMI analyst
Ask Us Your Questions About This Report@ https://www.futuremarketinsights.com/ask-question/rep-gb-16760
Competitive Landscape
Key players in the Severe Asthma Treatment market are Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Regeneron Pharmaceutical, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion
- The discovery and sale of a biologic medicine named Nucala by GlaxoSmithKline has been one of the company’s most significant achievements to the treatment of severe asthma (mepolizumab). Nucala is an anti-IL-5 monoclonal antibody used to treat severe eosinophilic asthma, a kind of severe asthma marked by high eosinophil levels in the blood and airways.
- The creation and sale of a biologic medicine named Xolair has been Novartis’ most significant contribution to the treatment of severe asthma (omalizumab). Xolair is an anti-IgE monoclonal antibody used to treat severe allergic asthma, which is caused by allergens such as pollen, dust mites, and animal dander.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Severe Asthma Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/16760
Key Segments Profiled in the Severe Asthma Treatment Industry Survey
Drug Class:
- Reslizumab
- Benralizumab
- Anti-inflammatory
Route of Administration:
- Oral
- Inhaled
- Intravenous
- Subcutaneous
Device Type:
- Dry powder inhalers
- Metered dose inhalers
- Soft mist inhalers
About the Healthcare at Future Market Insights
The healthcare domain team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 Billion+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
